From Rejection to Resubmission: Where the MDMA Drug Application Actually Stands

The regulatory story of MDMA-assisted therapy in the United States has two clearly dated moments and a long, unresolved argument between them. Understanding it is the fastest way to understand why this treatment is not available to American patients — and why it might be.

August 2024: the application is rejected

On 8 August 2024 the FDA issued a complete response letter rejecting Lykos Therapeutics' application for MDMA-assisted therapy for PTSD. The agency asked for two specific things: a new randomised, double-blind Phase 3 trial, and an independent audit of study records. A complete response letter is not a prohibition — it is a statement that the application cannot be approved as filed, plus a list of what would need to change.

The request for a new trial was the substantive objection. It followed an advisory committee that had found the efficacy case narrow and had raised concerns about whether participants and therapists could tell which arm they were in. The audit request concerned the conduct and reporting of the existing studies.

2024 to 2026: the sponsor's position hardens

Running a new Phase 3 trial costs hundreds of millions of dollars and several years. The sponsor's counter-argument, in outline, is that the existing Phase 3 programme — MAPP1 and MAPP2, both randomised, double-blind and placebo-controlled multi-site trials — already answers the question, and that a third trial would be an unreasonable burden on a small company developing a treatment for a condition with few options.

MAPS has published its own account of the programme, describing MAPP1 and MAPP2 as randomised, double-blind, placebo-controlled multi-site trials in 200 to 300 participants with severe PTSD of any cause, aged 18 and older. The registration for MAPP2 remains publicly viewable on ClinicalTrials.gov.

August 2026: resubmission without the trial

In August 2026 it was reported that Resilient Pharmaceuticals had resubmitted its application to the FDA without conducting a new Phase 3 trial, following the August 2024 complete response letter. If the report is accurate, the resubmission argues the existing evidence rather than new evidence — which places the agency in an awkward position: it must either accept evidence it previously called insufficient, or explain what specifically would satisfy it.

That is the state of play as of this writing. There is no approved MDMA-assisted therapy in the United States, and no approved timeline for one.

What the two sides are actually arguing

It is tempting to read this as regulators versus innovators. The disagreement is narrower and more technical than that:

• Blinding. Can a trial where the drug's effects are unmistakable support a claim of efficacy? The agency's position has been that it cannot without an active comparator or a different design; sponsors answer that no inert placebo can mimic MDMA.
• Effect attribution. With therapy in both arms and a large control-group response, how much of the benefit is the drug? The sponsor points to the gap between arms; the agency points to the size of the control response.
• Records. The audit request raised questions about conduct and reporting in the existing studies that are independent of any statistical argument.
• Proportionality. Is a new Phase 3 trial a reasonable requirement, or a de facto denial?

What to watch

Three things would move this: a formal FDA response to the resubmission, an announcement of a new trial, or a change in the trial design being proposed — for example an active comparator such as a proven trauma therapy, which would answer the central objection directly. Absent those, the practical situation for American patients is unchanged: no legal prescription route, and any clinic offering the treatment is operating outside an approved pathway.

We will keep this page updated as the application moves, and our Policy & Access section covers the Australian route in the meantime.